| 영문 | platelet | 한글 | 혈소판 |
|---|---|---|---|
| 설명 | 골수의 거대 세포인 거대핵세포의 세포질 일부가 떨어져서 순환 혈액 중에 출현한 것으로 직경이 2~4μm의 작은 과립체이다. 혈소판은 손상을 입은 혈관의 노출된 결합 조직에 붙어 여러 물질을 분비하여 지혈 및 혈액 응고에 중요한 역할을 한다. |
||
| 영문 | exchange transfusion | 한글 | 교환수혈 |
|---|---|---|---|
| 설명 | 한쪽으로는 피를 뽑아내면서 다른 쪽으로는 같은 양의 피를 넣어 온몸의 피를 갈아 넣는 수혈방법. 갓난아이의 용혈병의 치료법으로 쓴다. |
||
| 영문 | transfusion | 한글 | 수혈 |
|---|---|---|---|
| 설명 | 건강한 사람에게서 채취한 혈액을, 혈액이나 그 성분이 부족한 환자의 혈관 내에 주입하는 치료 방법. 수혈은 빈혈 또는 각종 대량 실혈과 수술시 피할 수 없는 출혈에 반드시 필요한 구명처치로서 환자의 혈액형에 적합한 양질의 혈액이 요구된다. 수혈은 보통 전혈을 정맥 내에 주입하지만, 때로는 골수 내 또는 동맥 내에 수혈할 때도 있다. 수혈하는 혈액도 전혈이 아닌 액상 성분인 냉장 또는 냉동혈장을 사용할 수 있고, 적혈구나 백혈구-혈소판과 같은 세포성분을 원심분리하여 귀중한 혈액을 더 아끼고 더 효과적으로 쓰고 있다. 수혈의 효과는 순환혈액량을 보충하여 혈압을 유지하고, 부족한 각종 혈액성분을 공급 조정하며, 조혈기능을 자극하는 일 등을 들 수 있다. 긴급한 수혈의 대상은 교통사고 등 외상에 의한 대출혈과 위궤양-자궁외임신 등에 따르는 병적 출혈과 각종 혈액질환에 수반되는 빈혈과 백혈구 및 혈소판 감소, 그리고 혈우병 환자나 다른 환자에서 볼 수 있는 혈액응고인자 부족과 화상환자-간질환 등에서 부족해진 혈장 또는 알부민의 보충과 면역체가 부족하여 감염증이 생긴 환자에게 부족한 항체를 포함한 혈액 또는 혈장제제를 주는 것도 이에 속한다. |
||
| 영문 | transfusion reaction | 한글 | 수혈부작용, 수혈반응 |
|---|---|---|---|
| 설명 | 수혈하였을 때에 환자에게 일어나는 반응. 알레르기 반응과 용혈 반응이 있다. |
||
| PA | panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'... |
|---|---|
| PAF | paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl... |
| PC | avoirdupois weight [Lat. pondus civile]; packed cells; paper chromatography; paracortex; parent cell... |
| PFKP | phosphofructokinase, platelet type; 6-phosphofructo-2-kinase, platelet type |
| PM | after death (Lat. post mortem); after noon [Lat. post meridiem]; mean pressure; pacemaker; pantomogr... |
| BT | Blood transfusion |
|---|---|
| DHTR | Delayed hemolytic transfusion reaction |
| DLT | Donor leukocyte transfusion |
| DST | Donor specific blood transfusion |
| DST | Donor-specific transfusion |
| platelet transfusion | The transfer of blood platelets from a donor to a recipient or reinfusion to the donor. (12 Dec 1998) |
|---|
| acquired platelet function defect | <haematology> Platelet function can be affected by a number of different disease processes including polycythaemia vera, leukaemia, myelofibrosis, renal failure, multiple myeloma and some medications (for example penicillins, salicylates, phenothiazines). Disturbed blood clotting can be manifested by: easy bruising, bleeding gums, nosebleeds, abnormal vaginal bleeding, rectal bleeding, skin rash, vomiting blood, coughing up blood or blood in the urine. A measure of bleeding time and coagulation profile will be part of the evaluation. (29 Dec 1997) |
|---|---|
| antigens, human platelet | Human alloantigens expressed only on platelets, specifically on platelet membrane glycoproteins. These platelet-specific antigens are immunogenic and can result in pathological reactions to transfusion therapy. (12 Dec 1998) |
| anti-platelet agents | Medications that, like aspirin, reduce the tendency of platelets in the blood to clump and clot. (12 Dec 1998) |
| receptors, platelet-derived growth factor | Specific molecular sites or structures on cell membranes that react with platelet-derived growth factor, its analogs, or antagonists, to elicit or to inhibit the specific response of the cell to this factor. Pdgf binds with different affinities and specificities to two structurally related receptors, the alpha-receptor and the beta-receptor. Both of these receptors are transmembrane proteins with an intracellular, ligand-stimulatable protein kinase domain. (12 Dec 1998) |
| medication, anti-platelet | Platelet-blocking drugs. Drugs that, like aspirin, reduce the tendency of platelets in the blood to clump and clot. (12 Dec 1998) |
| platelet | <haematology> A discoid cell (3m diameter) found in large numbers in blood, important for blood coagulation and for haemostasis by repairing breaches (small breaks) in the walls of blood vessels. Platelet _ granules contain lysosomal enzymes, dense granules contain ADP (a potent platelet aggregating factor) and serotonin (a vasoactive amine). They also release platelet-derived growth factor which presumably contributes to later repair processes by stimulating fibroblast proliferation. Synonym: thrombocytes. (09 Oct 1997) |
| platelet-activating factor | <cytokine> Potent phospholipid activator and mediator of many leucocyte functions, including platelet aggregation, inflammation, and anaphylaxis. It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells. Several molecular species of platelet-activating factor have been identified which vary in the length of the O-alkyl side chain. It is an important mediator of bronchoconstriction. Synonym: platelet-aggregating factor. Acronym: PAF (20 Sep 2002) |
| platelet activation | A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable haemostatic plug. (12 Dec 1998) |
| platelet actomyosin | The contractile protein of platelets, responsible for clot retraction, platelet aggregation, and release of ADP and other biologic amines essential to platelet function. Synonym: thrombosthenin. (05 Mar 2000) |
| platelet adhesiveness | The process whereby platelets adhere to something other than platelets, e.g., collagen, basement membranes, microfibrils, or other "foreign" surfaces. (12 Dec 1998) |
| platelet-aggregating factor | <cytokine> Potent phospholipid activator and mediator of many leucocyte functions, including platelet aggregation, inflammation, and anaphylaxis. It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells. Several molecular species of platelet-activating factor have been identified which vary in the length of the O-alkyl side chain. It is an important mediator of bronchoconstriction. Synonym: platelet-aggregating factor. Acronym: PAF (20 Sep 2002) |
| platelet aggregation | The attachment of platelets to one another. This clumping together can be induced by a number of agents (e.g., thrombin, collagen) and is part of the mechanism leading to the formation of a thrombus. (12 Dec 1998) |
| platelet aggregation inhibitors | Drugs or agents which antagonise or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (12 Dec 1998) |
| platelet aggregation test | A test of the ability of platelets to adhere to each other and hence form a haemostatic plug to prevent bleeding; failure to aggregate occurs in several conditions, e.g., thrombasthenia, Von Willebrand's disease, and following administration of aspirin, phenylbutazone, and indomethacin; the test is conducted by quantitating the decrease in turbidity that occurs in platelet-rich plasma following the in vitro addition of one or several platelet-aggregating agents (e.g., ADP, epinephrine, or serotonin). (05 Mar 2000) |
| platelet basic protein | <protein> Protein that is the precursor of connective tissue activating peptide III and _ thromboglobulin. (18 Nov 1997) |
Synonyms : Blood Platelet Transfusions, Platelet Transfusion, Blood, Platelet Transfusions, Platelet Transfusions, Blood, Transfusion, Blood Platelet, Transfusion, Platelet, Transfusions, Blood Platelet, Transfusions, Platelet
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|